Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 8, 2013, Pages 1676-1682

  Jinesh, Goodwin ^a   Lee, Eugene Kang ^a   Tran, Jonathan ^a   Kamat, Ashish M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BCG; Immunotherapy; Lenalidomide; Non muscle invasive bladder cancer

Indexed keywords

BCG VACCINE; CASPASE 3; LENALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CAPILLARY DENSITY; CELL CYCLE; CELL PROLIFERATION; CHROMATIN CONDENSATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; GOLD STANDARD; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; WESTERN BLOTTING;

BCG; IMMUNOTHERAPY; LENALIDOMIDE; NON-MUSCLE-INVASIVE BLADDER CANCER;

ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCG VACCINE; BLOTTING, WESTERN; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FAS LIGAND PROTEIN; FEMALE; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C3H; MICROVESSELS; THALIDOMIDE; TUMOR BURDEN; TUMOR NECROSIS FACTOR-ALPHA; URINARY BLADDER NEOPLASMS;

EID: 84886234754     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.05.007     Document Type: Article

References (30)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J Clin 2012, 2012:10-29.
2. Botteman M.F., Pashos C.L., Redaelli A., et al. The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics 2003, 21:1315-1330.
3. Morales A., Eidinger D., Bruce A.W. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976, 116:180-183.
4. Herr H.W., Laudone V.P., Badalament R.A., et al. Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988, 6:1450-1455.
5. Sylvester R.J., van der Meijden A.P., Witjes J.A., et al. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials. J Urol 2005, 174:86-91. Discussion -2.
6. Herr H.W., Schwalb D.M., Zhang Z.F., et al. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial. J Clin Oncol Off J American Society Of Clinical Oncology 1995, 13:1404-1408.
7. Sylvester R.J., van der Meijden A.P., Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol 2002, 168:1964-1970.
8. Herr H.W., Dalbagni G., Donat S.M. Bacillus Calmette-Guerin without maintenance therapy for high-risk non-muscle-invasive bladder cancer. Eur Urol 2011, 60:32-36.
9. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized southwest oncology group study. J Urol 2000, 163:1124-1129.
10. Steinberg G., Bahnson R., Brosman S., et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000, 163:761-767.
11. Davies F., Baz R. Lenalidomide mode of action: Linking bench and clinical findings. Blood Rev 2010, 24(Suppl 1):S13-S19.
12. Heise C., Carter T., Schafer P., et al. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. Expert Rev Anticancer Ther 2010, 10:1663-1672.
13. Dimopoulos M., Spencer A., Attal M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357:2123-2132.
14. Weber D.M., Chen C., Niesvizky R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357:2133-2142.
15. Soloway M.S. Single and combination chemotherapy for primary murine bladder cancer. Cancer 1975, 36:333-340.
16. DeKernion J.B., Soloway M.S., Persky L. Chemotherapy of experimental transitional-cell carcinoma. Urology 1974, 4:63-68.
17. Weldon T.E., Soloway M.S. Susceptibility of urothelium to neoplastic cellular implantation. Urology 1975, 5:824-827.
18. Kamat A.M., Tharakan S.T., Sung B., et al. Curcumin potentiates the antitumor effects of bacillus Calmette-Guerin against bladder cancer through the down-regulation of NF-κB and up-regulation of TRAIL receptors. Cancer Res 2009, 69:8958-8966.
19. Sosnowski J.T., De Haven J.I., Abraham F.M., et al. Sequential immunocytological evaluation of murine transitional cell carcinoma during intralesional bacillus Calmette-Guerin and interleukin-2 immunotherapy. J Urol 1992, 147:1439-1443.
20. Lamm D.L., Riggs D.R., DeHaven J.I., et al. Immunotherapy of murine bladder cancer by irradiated tumor vaccine. J Urol 1991, 145:195-198.
21. Scott I.S., Morris L.S., Bird K., et al. A novel immunohistochemical method to estimate cell-cycle phase distribution in archival tissue: Implications for the prediction of outcome in colorectal cancer. J Pathol 2003, 201:187-197.
22. Crane E., List A. Lenalidomide: An immunomodulatory drug. Futures Oncol 2005, 1:575-583.
23. Suttmann H., Riemensberger J., Bentien G., et al. Neutrophil granulocytes are required for effective bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 2006, 66:8250-8257.
24. Jinesh G.G., Chunduru S., Kamat A.M. Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL. J Leukoc Biol 2012 Apr 19, [Epub ahead of print].
25. Marriott J.B., Clarke I.A., Dredge K., et al. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002, 130:75-84.
26. Bui T.T., Schellhammer P.F. Additional bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology 1997, 49:687-690. Discussion 90-1.
27. Cheng L., Weaver A.L., Leibovich B.C., et al. Predicting the survival of bladder carcinoma patients treated with radical cystectomy. Cancer 2000, 88:2326-2332.
28. Stein J.P., Skinner D.G. Results with radical cystectomy for treating bladder cancer: A 'reference standard' for high-grade, invasive bladder cancer. BJU Int 2003, 92:12-17.
29. Richardson P.G., Schlossman R.L., Weller E., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100:3063-3067.
30. Chan E.S., Patel A.R., Smith A.K., et al. Optimizing orthotopic bladder tumor implantation in a syngeneic mouse model. J Urol 2009, 182:2926-2931.